Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT04394065 Completed - Clinical trials for Nasopharyngeal Carcinoma

uEXPLORER Total-body PET/CT in Nasopharyngeal Carcinoma

Start date: June 20, 2020
Phase:
Study type: Observational [Patient Registry]

uEXPLORER total-body PET/CT in Nasopharyngeal Carcinoma

NCT ID: NCT04387266 Completed - Clinical trials for Nasopharyngeal Carcinoma

To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC

Start date: June 1, 2020
Phase:
Study type: Observational

This is a retrospective real-world study to evaluate the efficacy and feasibility of modified reduce-volume target IMRT in the treatment of patients with non-metastatic NPC

NCT ID: NCT04384627 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy

NPC-GTV
Start date: December 1, 2019
Phase: Phase 3
Study type: Interventional

To evaluate the long-term locoregional control, survival rate, late toxicity and quality of life after reducing the target volume in patients with locoregionally advanced nasopharyngeal carcinoma patients treated with induction chemotherapy plus concurrent chemoradiotherapy.

NCT ID: NCT04376866 Recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Start date: June 28, 2020
Phase: Phase 3
Study type: Interventional

This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy alone in treating patients with locoregionally recurrent nasopharyngeal carcinoma.

NCT ID: NCT04351282 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Primary metastatic NPC patients received chemotherapy± immunotherapy, radiation for primary tumors and SBRT for metastatic lesions.

NCT ID: NCT04350190 Completed - Clinical trials for Nasopharyngeal Carcinoma

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Start date: January 14, 2021
Phase: Phase 2
Study type: Interventional

The study is to evaluate the clinical efficacy of apatinib mesylate tablets combined with PD-1 in the treatment of recurrent and metastatic nasopharyngeal carcinoma after IMRT with concurrent chemotherapy,including The Overall Response Rate (ORR), Progression-free survival (PFS),Overall survival (OS),and Toxicities.

NCT ID: NCT04340024 Recruiting - Prostate Cancer Clinical Trials

Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients

Start date: September 30, 2015
Phase:
Study type: Observational

Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.

NCT ID: NCT04319471 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of sufficient chemoradiotherapy plus oral capecitabine/S-1 for 1 year in the treatment of oligometastatic Nasopharyngeal Carcinoma

NCT ID: NCT04303975 Not yet recruiting - Clinical trials for Head and Neck Cancer

The Association of hsCRP and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma

Start date: June 2021
Phase:
Study type: Observational

The primary purpose of this study is to explore the association of high sensitivity C-reactive protein (hsCRP) and radiotherapy(RT)-induced toxicity in patients with nasopharyngeal carcinoma. In each patient, hsCRP levels in the pre- and post-RT plasma samples will be measured according to the schedule we set.

NCT ID: NCT04292990 Not yet recruiting - Pain Clinical Trials

Comparison of Transdermal Fentanyl and Morphine for Oral Mucositis Pain in Nasopharyngeal Cancer Patients

Start date: December 2020
Phase: Phase 4
Study type: Interventional

The primary purpose of this study is to explore the significance of analgesic treatment for radiation-induced oral mucositis pain in patients with nasopharyngeal carcinoma during radiotherapy, and to compare the analgesic effect of morphine controlled-release tablets with that of fentanyl transdermal patch. Half of participants will receive morphine controlled-release tablets,while the other half will receive fentanyl transdermal patch.